Olfactory neuroblastoma: 14-year experience at an Australian tertiary centre and the role for longer-term surveillance

• Published in: Journal of laryngology and otology Vol. 131; no. S2; p. S29
• Main Authors: Schmidt, C, Potter, N, Porceddu, S, Panizza, B
• Format: Journal Article
• Language: English
• Published: England 01-07-2017
• Subjects: Aged; Aged, 80 and over; Cancer Care Facilities - statistics & numerical data; Esthesioneuroblastoma, Olfactory - mortality; Esthesioneuroblastoma, Olfactory - surgery; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasal Cavity - surgery; Nose Neoplasms - mortality; Nose Neoplasms - surgery; Patient Care Team - statistics & numerical data; Queensland - epidemiology; Retrospective Studies; Treatment Outcome; Neoplasm; Olfactory Neuroblastoma; Relapse; Surveillance; Esthesioneuroblastoma; Metastasis; Survival
• ISSN: 1748-5460
• DOI: 10.1017/S0022215116009592

Olfactory neuroblastoma is a rare sinonasal malignancy, with poorly defined treatment protocols. Management at a tertiary centre was retrospectively evaluated to inform future treatment and follow up.
Cases treated with curative intent (2000-2014) were included. Data were collected, and overall and disease-free survival rates were calculated.
Eleven cases were identified, with a median follow up of 87 months. One patient was Kadish stage A, one was stage B, eight were stage C and one was stage D. The latter patient underwent chemoradiotherapy alone. The remaining patients proceeded to: endoscopic-assisted wide local excision (n = 2), anterior craniofacial resection (n = 4) or endoscopic craniofacial resection (n = 4). No patients had primary nodal disease or elective neck treatment. One patient had neoadjuvant chemoradiation. Six patients had post-operative radiotherapy; three received adjuvant chemotherapy. Two patients had late cervical node failure, and proceeded to neck dissection and post-operative radiotherapy. Two patients had late local recurrence. Ten-year overall and disease-free survival rates were 68.2 and 46.7 per cent, respectively.
Longer-term follow up is supported given the incidence of late regional and local recurrence. Prophylactic treatment of cervical nodes in locally advanced disease is an area for further investigation.